Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF FOSTER CITY, Calif. & MECHELEN, Belgium (BUSINESS WIRE)
Galapagos NV (Euronext & Nasdaq: GLPG) and Gilead Sciences (Nasdaq: GILD) today announced the decision to halt the ISABELA Phase 3 clinical studies with the investigational autotaxin inhibitor ziritaxestat in patients with idiopathic pulmonary fibrosis. The decision is based on the recommendations of the Independent Data Monitoring Committee (IDMC) which, following a regular review of unblinded data, concluded that ziritaxestat’s benefit-risk profile no longer supported continuing these studies. Detailed data of the ISABELA studies will be presented at future medical meetings.
Investigators are being informed of the decision and they will be contacting their study participants to discontinue the investigational treatment.
FOSTER CITY (dpa-AFX) - Galapagos NV (GLPG) and Gilead Sciences (GILD) said that they have decided to discontinue the ISABELA Phase 3 studies with the investigational autotaxin inhibitor ziritaxestat
Janssen Pharmaceutica NV: Janssen Announces Treatment with ERLEADA?(apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer
FOR EMEA PHARMACEUTICAL TRADE AND MEDICAL MEDIA ONLY NOT FOR DISTRIBUTION IN BENELUX, SWEDEN AND ITALY
Janssen Pharmaceutica NV (Janssen) announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of apalutamide plus androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) when compared to placebo plus ADT.
1 Results will be featured in an oral presentation at the American Society of Clinical Oncology s Genitourinary (ASCO GU) Cancers Symposium, taking place virtually February 11-13, 2021 (Abstract #11; Rapid Abstract Session: Prostate Cancer, February 11 9:30 PM-10:15 PM CET).
Top Story
February 9, 2021
ISLAMABAD: Special Assistant to the Prime Minister (SAPM) on Health Dr Faisal Sultan on Monday announced that China’s CanSinoBio COVID-19 vaccine is nearly 75% effective against the virus in Pakistan.
Taking to Twitter, the special assistant said that according to the vaccine’s phase-three trials data, it has turned out to be 74.8% effective against the virus, while it also showed 100% effectiveness in preventing severe disease.
Further citing the Independent Data Monitoring Committee’s report, he said that in multiple countries, the vaccine was 65.7% and 90.98% effective in preventing symptomatic cases and severe diseases, respectively.
The SAPM said that the IDMC did not report any “serious safety concerns” and that the data included as many as 30,000 participants and 101 people who had tested positive for coronavirus. At the beginning of February, China’s CanSino Biologics had said that an independent committee found the drugmaker’s C